Recommended Conferences

Genetic Engineering and Gene Therapy

Paris, France

Human Genetics and Genetic Disorders

Miami, USA

Tissue Engineering and Regenerative Medicine

Chicago, USA
Related Subjects
 

Interleukin 6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes

Author(s): Grossman RM, Krueger J, Yourish D, Granelli-Piperno A, Murphy DP, et al.

Abstract

Psoriasis is a common papulosquamous skin disease. The histopathology is characterized by epidermal hyperplasia and inflammation. Recent studies suggest that keratinocyte proliferation and inflammation in psoriasis are manifestations of the same underlying pathological process. Interleukin 6 (IL-6), a cytokine that is a major mediator of the host response to tissue injury and infection, is produced by both keratinocytes and leukocytes in culture. IL-6 expression was studied in psoriatic plaques by immunoperoxidase staining with two different polyclonal anti-recombinant IL-6 antisera and by in situ nucleic acid hybridization with IL-6 cRNA probes. Epidermal and dermal cells in active psoriatic plaques from 35 psoriasis patients stained heavily for IL-6 as compared with nonlesional skin and with plaques after treatment with antimetabolic and antiinflammatory agents. Absorption of the anti-recombinant IL-6 antisera with purified fibroblast-derived IL-6 or with recombinant IL-6, but not bovine serum albumin, removed the immunostaining. Increased levels of IL-6 were detected in the plasma of patients with active psoriasis (mean 3 ng/ml) by using two different bioassays. IL-6 production by proliferating keratinocytes was suggested by IL-6-specific immunostaining in cultured normal and psoriatic keratinocytes and by the detection of mRNA specific for IL-6 in psoriatic epidermis by in situ hybridization. IL-6 stimulated the proliferation of cultured, normal human keratinocytes as assessed by two different assays. Thus, IL-6 could directly contribute to the epidermal hyperplasia seen in psoriatic epithelium as well as affect the function of dermal inflammatory cells.

Similar Articles

Psoriasis: dysregulation of innate immunity

Author(s): Bos JD, de Rie MA, Teunissen MB, Piskin G

Pathogenesis and therapy of psoriasis

Author(s): Lowes MA, Bowcock AM, Krueger JG

Interleukine-1 and interleukine- 6 in psoriasis

Author(s): Prens EP, Benne K, van DJ, Bakkus M, Brakel K, et al.

The IL-23/ Th 17 Axis in the Immunopathogenesis of Psoriasis

Author(s): Cesare DC, Meglio PD, Nestle FO

Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial

Author(s): Chaudhari U, Romano P, Mulcahy L, Dooley L, B aker D, et al.

Demonstration of novel innate immune cells in psoriasis

Author(s): Mak R, Hundhausen C, Botti E, Laggner U, Grys K, et al.

Histopathologic spectrum of psoriasis

Author(s): Murphy M, Philip K, Grant- Kels JM